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633hypertension, a more precise inﬂuence of total adi-
posity may be obtained. This is important because
the cardiometabolic risk of many patients may be
underestimated when using BMI because it cannot
always properly discriminate the risk of chronic
disease at the individual level (4).
Data from the study by Chandra et al. (1) reinforce
the notion that focusing on body composition, rather
than BMI, when screening for obesity and overweight
may be helpful to better estimate cardiometabolic
risk in clinical practice (5).*Javier Gómez-Ambrosi, PhD
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crinol 2012;8:570–2.REPLY: Does Body Adiposity Better Predict
Obesity-Associated Cardiometabolic Risk
Than Body Mass Index?We thank Dr. Gómez-Ambrosi and colleagues for their
insights regarding our paper (1). We agree completely
with the notion that body mass index (BMI) has lim-
itations with regard to measuring adiposity, although
it certainly remains the most clinically used measure
of adiposity. For this reason, we believed it was an
important component to add to our multivariate
modeling.
As suggested, we did have access to data on
total body fat as measured by dual-energy x-ray ab-
sorptiometry; however, because this is not acommonly used measure of total adiposity, we did
not choose to use it in our multivariate modeling.
Nonetheless, total fat mass determined by dual-
energy x-ray absorptiometry was, like body mass
index, found to be highly associated with the devel-
opment of hypertension after adjusting for age,
baseline systolic blood pressure, sex, race/ethnicity,
history of smoking, and diabetes mellitus (relative
risk [RR]: 1.27; 95% conﬁdence interval [CI]: 1.14 to
1.41; p < 0.0001). However, as in the original analysis,
this association is attenuated when visceral adipose
tissue is included in the model (RR: 1.20; 95% CI: 0.89
to 1.62; p ¼ 0.24) while visceral adipose tissue re-
mains signiﬁcant (RR: 1.20; 95% CI: 1.04 to 1.39;
p ¼ 0.012). Thus, despite the addition of a more ac-
curate measure of total adipose mass, our conclusion
appears to remain the same, namely that visceral
adipose tissue is the adipose tissue depot most asso-
ciated with incident hypertension.Alvin Chandra, MD
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Studies of Culprit Lesions
Before MIWe read with interest the excellent editorial by Nar-
ula and Kovacic (1). This letter is to clarify issues in
the ﬁrst paragraph about our serial angiographic
studies of culprit lesions before myocardial infarction
(MI) (2,3).
We agree that the culprit occlusion causing an
MI contains usually substantial atherosclerosis with
superimposed thrombus. Furthermore, pathological
and cross-sectional intracoronary imaging shows that
the culprit usually produces a high-grade stenosis
(>90%). However, these observations are not incon-
sistent with our reports that the culprit frequently did
not contain a signiﬁcant angiographic stenosis when
evaluated before MI (2,3). The conclusions of our
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634retrospective studies were recently conﬁrmed in the
prospective PROSPECT (Providing Regional Observa-
tions to Study Predictors of Events in the Coronary
Tree) study, in which the mean angiographic stenosis
of lesions without intervention that subsequently
produced ischemic events was 32% (4). The expla-
nation for the apparent conﬂict is the difference
in how stenoses are measured. Pathological exami-
nation and cross-sectional imaging measure the
stenosis as the reduction in cross-sectional area
(CSA); angiographically, the stenosis is reported as a
reduction in lumen diameter. A 75% reduction in CSA
is the equivalent of a 50% reduction in diameter (5).
Even a 90% reduction in CSA is a <70% reduction
in cross-sectional diameter. In addition, positive
remodeling increases the reference CSA but not the
reference diameter. Thus, a 90% cross-sectional ste-
nosis may be an angiographically insigniﬁcant diam-
eter stenosis <50%.
It is clear that the presence of vulnerable plaques
and the risk of subsequent occlusion are highest in
areas of the coronary tree with high-grade stenoses.
Some may occlude silently. However, areas without
severe stenosis may also contain vulnerable plaques
and are not risk-free, and importantly these non-
stenotic areas are much more common and may
transform over time to more severe occlusion and
acute events. Thus, much of the risk for a subsequent
MI is in areas without angiographic stenosis. Anangiographically “insigniﬁcant” diameter stenosis
does not indicate insigniﬁcant atherosclerosis or
freedom from risk of subsequent events.
These clariﬁcations serve only to strengthen the
important conclusion of Narula and Kovacic (1) that
advances in imaging beyond coronary angiography
have enhanced our understanding of the culprits in
MI, but for now our therapeutic focus must be on the
entire atherosclerotic process.*William C. Little, MD
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